BioAtla, Inc. (BCAB) BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
BioAtla, Inc. OTC:BCAB Healthcare · Biotechnology
All Press Release SEC Filings News
SEC Filing ● Major ⚠ 5
BCAB: 8-K · material agreement
BioAtla entered into a $40.0 million Standby Equity Purchase Agreement with Yorkville (YA II PN, Ltd.) on October 15, 2026, replacing a terminated $15.0 million prior SEPA under which only ~$0.4 million had been drawn. The Company has the right, but no obligation, to sell shares to Yorkville over 36 months, with each advance capped at 100% of average daily trading volume and priced at 97% of the lowest daily VWAP during a 3-day pricing period.
SEC 8-K • 7d ago AI analysis › SEC Filing ⚠ 5
BCAB: 8-K · leadership change
BioAtla announced that Chief Medical Officer Dr. Eric Sievers resigned effective September 25, 2026, to pursue outside interests, and will remain a consultant through June 30, 2027 under a new consulting agreement.
His consulting deal includes a one-time $159,000 payment contingent on BioAtla achieving certain capital raising milestones by December 31, 2026.
The board also reinstated retention bonuses for CEO Jay Short ($440,892 target) and CFO Christian Vasquez ($148,888 target), both tied to capital raising milestones by year-end — after the original milestones due in May and August 2026 were missed — plus new performance bonuses of $220,000 and $75,000 tied to milestones by March 31, 2027.
The repeated reliance on capital-raising milestones across compensation arrangements underscores funding pressure amid an ongoing strategic process at the clinical-stage biotech, which now trades on the OTCQB market.
SEC 8-K • 27d ago AI analysis › SEC Filing ● Critical ⚠ 5
BCAB: 8-K · delisting
On August 26, 2026, the Nasdaq Listing and Hearing Review Council affirmed the Hearings Panel's determination to delist BioAtla's common stock from Nasdaq, and trading will be suspended at the opening of business on August 31, 2026 unless the Nasdaq Board calls the matter for review. A Form 25-NSE will then be filed to remove the shares from Nasdaq listing and registration.
The delisting stems from BioAtla's non-compliance with the $1.00 minimum bid price rule and its failure to demonstrate compliance with the $2.5 million stockholders' equity requirement, despite previously meeting the $35 million market-value-of-listed-securities alternative for 69 consecutive trading days.
Once suspended, BCAB is expected to be immediately eligible for quotation on the OTC Markets system under its current symbol, but the company warned the move may have a material adverse effect on trading price and volume and that stockholders may find it more difficult to buy or sell shares.
BioAtla's strategic alternatives process initiated in March 2026 remains ongoing with no assurance of any transaction, and the filing's forward-looking statements reiterate going-concern risk and the need for additional funding to continue developing its CAB technology platform and product candidates.
SEC 8-K • 1mo ago AI analysis › SEC Filing ● Critical ⚠ 8
BCAB: 10-Q · periodic report
BioAtla reported Q2 2026 collaboration revenue of $6.5 million from the amended Context Therapeutics license, producing net income of $452,000 versus an $18.7 million loss a year earlier. R&D expense fell to $3.3 million from $13.7 million after a 70% workforce reduction in March 2026.
Management disclosed substantial doubt about the company's ability to continue as a going concern, with only $1.5 million in cash at June 30, 2026. The company launched a strategic alternatives process on March 2, 2026 and paused enrollment in its Phase 1 BA3182 trial while reassessing the BA3021 Phase 3 timeline.
BioAtla is currently not in compliance with Nasdaq continued listing requirements following a 50-for-1 share consolidation effective April 6, 2026, leaving roughly 1.67 million shares outstanding. Risk factors warn the company may be forced to cease operations or file for bankruptcy protection if a strategic transaction is not completed.
SEC 10-Q • 2mo ago AI analysis › SEC Filing
BCAB: 8-K · proxy statement
BioAtla, Inc. announced the voting results from its Annual Meeting of Stockholders held on July 16, 2026, where stockholders approved all proposals presented for a vote.
Shareholders elected Jay M. Short, Ph.D. and Edward Williams as Class III directors to serve three-year terms on the Board of Directors, with each nominee receiving majority support.
Additionally, the company ratified the appointment of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved a non-binding advisory resolution on executive compensation.
SEC 8-K • 3mo ago SEC Filing ⚠ 4
BCAB: DEF 14A · proxy statement
BioAtla, Inc. (BCAB) filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders, confirming a 50-for-1 share consolidation effected on April 6, 2026. All share counts and per-share amounts in the filing are retroactively adjusted to reflect this reverse split, which reduced the outstanding share count to approximately 1.66 million shares.
The proxy discloses the departure of Scott Smith from the Board of Directors following the annual meeting, reducing the board size from seven to six members. It also confirms the appointment of Christian Vasquez as Chief Financial Officer, succeeding Richard A. Waldron, who served as CFO during the 2025 fiscal year.
The filing highlights a proposed but unclosed transaction with related party Inversagen AI LLC, involving a $40 million sale of units in a subsidiary holding rights to ozuriftamab vedotin. The company states this transaction has not closed and is being re-evaluated due to a formal process to explore strategic options and recent workforce reductions.
SEC DEF 14A • 4mo ago Press Release
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
Context Therapeutics amended its license agreement with BioAtla for CT-202, removing BioAtla's future milestone and royalty obligations in exchange for total payments of $6.5 million.
The deal structure includes a $4.5 million upfront payment and a second installment of $2.0 million due by August 1, 2026.
Context expects to initiate the Phase 1 clinical trial for CT-202, a Nectin-4 x CD3 T cell engager, in the third quarter of 2026.
• 5mo ago AI analysis › SEC Filing ● Major ⚠ 7
BCAB: 10-Q · periodic report
BioAtla (BCAB) reported a Q1 2026 net loss of $6.3 million and disclosed substantial doubt about its ability to continue as a going concern, citing only $2.0 million in cash against a $552 million accumulated deficit. The company has initiated a formal process to explore strategic options, including the sale of assets or a potential merger, while simultaneously implementing a 70% workforce reduction to preserve capital.
To address immediate liquidity needs, BioAtla entered into an amendment to its license agreement with Context Therapeutics, securing $6.5 million in payments ($4.5 million due within five business days and $2.0 million by August 2026). This amendment converts the license to an irrevocable, royalty-free, fully paid-up arrangement, effectively selling off the rights to the BA3362 program in exchange for near-term cash.
The filing also reflects the retroactive impact of a 50-for-1 reverse stock consolidation effective April 6, 2026, which reduced the share count to approximately 1.66 million shares. While the company has a $15 million Standby Equity Purchase Agreement (SEPA) with Yorkville, it has only drawn $0.4 million under this facility in Q1, signaling limited access to or willingness to utilize this capital source amid the strategic review.
SEC 10-Q • 5mo ago AI analysis › Recent SEC filings with analysis 
